dc.contributor.author | Harneshaug, Magnus | |
dc.contributor.author | Kirkhus, Lene | |
dc.contributor.author | Saltyte Benth, Jurate | |
dc.contributor.author | Grønberg, Bjørn Henning | |
dc.contributor.author | Bergh, Sverre | |
dc.contributor.author | Whist, Jon Elling | |
dc.contributor.author | Rostoft, Siri | |
dc.contributor.author | Jordhøy, Marit Slaaen | |
dc.date.accessioned | 2020-08-05T11:49:30Z | |
dc.date.available | 2020-08-05T11:49:30Z | |
dc.date.created | 2018-07-30T12:32:02Z | |
dc.date.issued | 2018 | |
dc.identifier.citation | Journal of Geriatric Oncology. 2018, . | en_US |
dc.identifier.issn | 1879-4068 | |
dc.identifier.uri | https://hdl.handle.net/11250/2670951 | |
dc.description.abstract | Introduction: As frailty is associated with inflammation, biomarkers of inflammation may represent objective measures that could facilitate the identification of frailty. Glasgow prognostic score (GPS), combines C-reactive protein (CRP) and albumin, and is scored from 0 to 2 points. Higher score indicates a higher degree of inflammation.
Objectives: To investigate whether (1) GPS is associated with frailty, (2) GPS could be used to screen for frailty, (3) IL-6 and TNF-α add to the accuracy of GPS as a screening tool, and (4) GPS adds prognostic information in frail older patients with cancer.
Methods: Prospective, observational study of 255 patients ≥70 years with solid malignant tumours referred for medical cancer treatment. At baseline, frail patients were identified by a modified Geriatric Assessment (mGA), and blood samples were collected.
Results: Mean age was 76.7 years, 49.8% were frail, and 56.1% had distant metastases. The proportion of frail patients increased with higher GPS (GPS zero: 43.2%, GPS one: 52.7%, GPS two: 94.7%). GPS two was significantly associated with frailty (OR 18.5), independent of cancer type, stage, BMI and the use of anti-inflammatory drugs. The specificity of GPS was high (99%), but the sensitivity was low (14%). Frail patients with GPS two had poorer survival than patients with GPS zero-one. TNF-α and IL-6 did not improve the accuracy of GPS when screening for frailty.
Conclusion: Frailty and GPS two are strongly associated, and GPS two is a significant prognostic factor in frail, older patients with cancer. The inflammatory biomarkers investigated are not suitable screening tools for frailty. | en_US |
dc.description.sponsorship | This study was funded by Innlandet Hospital Trust (0303 150337). | en_US |
dc.language.iso | eng | en_US |
dc.rights | Navngivelse-Ikkekommersiell-DelPåSammeVilkår 4.0 Internasjonal | * |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.no | * |
dc.subject | Cancer | en_US |
dc.subject | inflammation | en_US |
dc.subject | biomarkers | en_US |
dc.subject | Glasgow prognostic score (GPS) | en_US |
dc.subject | C-reactive protein (CRP) | en_US |
dc.subject | frailty | en_US |
dc.subject | malignant tumours | en_US |
dc.subject | blood samples | en_US |
dc.subject | Frailty and GPS | en_US |
dc.subject | poorer survival | en_US |
dc.subject | older patients | en_US |
dc.subject | Geriatric Assessment (mGA) | en_US |
dc.subject | medical cancer treatment | en_US |
dc.title | Screening for frailty among older patients with cancer using blood biomarkers of inflammation | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | acceptedVersion | en_US |
dc.rights.holder | Copyright © 2018 Elsevier Inc. All rights reserved. | en_US |
dc.source.pagenumber | 7 | en_US |
dc.source.volume | 10 | en_US |
dc.source.journal | Journal of Geriatric Oncology | en_US |
dc.source.issue | 2 | en_US |
dc.identifier.doi | 10.1016/j.jgo.2018.07.003 | |
dc.identifier.cristin | 1598963 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.fulltext | postprint | |
cristin.qualitycode | 1 | |